Shelley Wood

Conference news filled our list this month, dominated by TCT 2024, although two EACTS stories also cracked our top 10.

The 2024 conference has 28 late-breakers plus plenty of basic and population science. More than anything, it’s a celebration.

(UPDATED) The trial, which was stopped early for futility, raises questions about the link between anticoagulation and neurocognition.

(UPDATED) The mixed, counterintuitive results hinder trial interpretation, but along with ARREST-AF, experts still see actionable results.

News from the American Heart Association 2024 Scientific Sessions took seven of the 10 top slots this month.

Touchy topics, timely analysis, tips for tackling entrenched problems: enjoy some of TCTMD’s best features this year.

Sugar substitutes, substance abuse, GLP-1 drugs, and the biggest clinical trials of the year—each had their place in our top 10.

All entries were placed in a draw for one free registration to the TCT meeting and two Platinum memberships for TCTMD.

January saw almost every major cardiovascular subspecialty represented among our most-clicked stories of the month.

Top news this month spans heart failure, ASCVD, structural heart disease, policy news, and more.